



US005639724A

United States Patent [19]**Cavanak****[11] Patent Number: 5,639,724****[45] Date of Patent: Jun. 17, 1997****[54] CYCLOSPORIN GALENIC FORMS****[75] Inventor:** Thomas Cavanak, Biel-Benken,
Switzerland**[73] Assignee:** Sandoz Ltd., Basel, Switzerland**[21] Appl. No.:** 163,193**[22] Filed:** Dec. 6, 1993**Related U.S. Application Data**

[63] Continuation of Ser. No. 940,119, Sep. 3, 1992, abandoned, which is a continuation of Ser. No. 822,375, Jan. 17, 1992, abandoned, which is a continuation of Ser. No. 481,082, Feb. 16, 1990, abandoned, which is a continuation-in-part of Ser. No. 462,373, Jan. 9, 1990, abandoned, which is a continuation of Ser. No. 373,736, Jun. 29, 1989, abandoned, which is a continuation of Ser. No. 193,896, May 13, 1988, abandoned, which is a continuation of Ser. No. 901,356, Aug. 28, 1986, abandoned, which is a continuation of Ser. No. 633,808, Jul. 24, 1984, abandoned.

[30] Foreign Application Priority Data

Feb. 20, 1989 [GB] United Kingdom 8903804

[51] Int. Cl.⁶ A61K 38/13; A61K 47/14**[52] U.S. Cl.** 514/11; 514/785; 514/786**[58] Field of Search** 514/9, 11, 885,
514/786, 974, 785; 530/317, 321**[56] References Cited****U.S. PATENT DOCUMENTS**3,288,824 11/1966 Mahler et al. 426/653
4,108,985 8/1978 Ruegger et al. 514/11

4,210,581	7/1980	Ruegger et al.	530/321
4,220,641	9/1980	Traber et al.	514/11
4,388,307	6/1983	Cavanak	514/2
4,719,239	1/1988	Muller et al.	514/785
4,996,193	2/1991	Hewitt et al.	514/11

FOREIGN PATENT DOCUMENTS

895724	7/1983	Belgium .
2098865	12/1982	United Kingdom .

OTHER PUBLICATIONS

Chem. Abstracts, vol. 95, No. 225610k (1981).

Eckert et al., Chem Abstr., vol. 89, No. 117875t (1978).

Cavanak, Chem Abstr. vol. 92, No. 64765k (1980).

Simpson et al., Chem. Abstr., vol. 94. No. 327c (1981).

Primary Examiner—Jeffrey E. Russel*Attorney, Agent, or Firm*—Robert S. Honor; Carl W. Battle**[57] ABSTRACT**

Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.

22 Claims, No Drawings